Annapolis, MD
— Governor Wes Moore today joined leaders from Samsung Biologics and local officials for the ribbon-cutting of the company’s
first United States manufacturing facility in Rockville, Maryland. The $353 million acquisition of the manufacturing campus retains over 500 local jobs, brings an additional 60,000 liters of drug substance capacity to the company’s operations, and establishes a foundation for future facility investment and expansion.
“During our international trade mission last year, we met with the Samsung Biologics team in Seoul to discuss the economic momentum in Maryland. Today’s ribbon cutting is the realization of that meeting and our state’s momentum,” said Gov. Moore. “South Korea’s largest biotech company is opening its first U.S. manufacturing facility here in Maryland. In the state of Maryland, we are delivering for our people and not playing for second.”
Headquartered in Songdo, Incheon, Samsung Biologics is a global biotechnology company focused on the development, manufacturing, and commercialization of biologic drugs. The new Rockville facility comprises two manufacturing plants supporting both clinical and commercial biologics production, boosting the company’s total global capacity to 845,000 liters. In the coming months, the company plans to evaluate existing site capabilities and equipment for further capacity expansion, technology upgrades, and additional capital investments.
Maryland’s thriving biopharmaceutical sector and its proximity to world-class universities and federal facilities drove the decision to locate the facility in Rockville. With this new facility, Samsung Biologics establishes a critical foothold to execute its long-term strategy to expand in the U.S. market.
“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,” said Samsung Biologics President and Chief Executive Officer John Rim. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”
“Samsung Biologics’ investment in Montgomery County is a major win for Maryland and a clear example of how public investment and global partnerships help drive innovation, business and workforce opportunities and improve the health and well-being of our communities,” said Congresswoman April McClain Delaney. “As a member of the House Science, Space, and Technology Committee, I have seen how sustained federal support for research helps attract cutting-edge companies to our region. Located along the I-270 Technology Corridor, this new facility will benefit from Maryland’s uniquely collaborative innovation ecosystem—where federal labs, universities, and industry collaborate to drive progress. We’re proud to welcome Samsung Biologics to our science community and to celebrate their new facility.”
“Samsung Biologics is a global leader in biomanufacturing, known for excellence, scale, and precision, and their decision to establish their first U.S. biomanufacturing presence in Montgomery County, Maryland speaks volumes about our attractiveness to international companies,” said Montgomery County Executive Marc Elrich. “Montgomery County sits at the heart of the nation’s third-largest biohealth cluster. We are home to the National Institutes of Health, the U.S. Food and Drug Administration, and the University of Maryland’s Institute for Health Computing, alongside a dynamic cluster of private sector companies advancing breakthroughs in biotech, R&D, manufacturing, and health innovation. We are proud to be a County and State designed to move ideas from discovery to delivery. We welcome Samsung Biologics to Montgomery County.”
“We are thrilled and appreciative that Samsung Biologics decided to establish its first U.S. manufacturing campus in the greater Rockville, Maryland Biotech Corridor, one of the nation’s leading biotech hubs,” said Rockville Mayor Monique Ashton. “This is so much more than a brick building being filled. This expansion will bring global leadership in biomanufacturing to Rockville, it will be a source of life-saving therapies for patients around the world, and it will foster sustained economic opportunity for our region—supporting hundreds of skilled jobs today while laying the foundation for future growth in our life sciences workforce.”
“We are proud to join the State of Maryland and Montgomery County in welcoming Samsung Biologics to Rockville and celebrating this important milestone,” said Montgomery County Economic Development Corporation President and Chief Executive Officer Jared Smith. “This decision reflects the confidence global industry leaders have in our business environment. Samsung Biologics’ presence will further strengthen our life sciences ecosystem and help drive meaningful opportunities for innovation, collaboration, and economic growth.”
The launch of the Samsung Biologics facility builds on a series of historic commitments from internationally-based companies to expand Maryland’s life sciences and biopharmaceutical sectors. The announcement follows Governor Moore’s international trade and investment mission to Japan and South Korea to promote economic growth and workforce development. During the mission, the governor met with Samsung Biologics executives in Seoul; addressed the Korea Trade-Investment Promotion Agency and Korea International Trade Association—two of Korea’s largest business organizations; and held engagements in Japan to strengthen ties in quantum, life sciences, and artificial intelligence.
“Samsung Biologics joins one of the top biopharma clusters in the country with this move into Maryland,” said Maryland Department of Commerce Secretary Harry Coker, Jr. “With its innovative portfolio and dedication to life-saving therapeutics, the company’s impact is felt throughout the world. Maryland is honored to play a role in that important work.”
“Samsung Biologics’ arrival in Rockville is a defining milestone in a relationship built on years of mutual respect, cultural exchange, and friendship,” said Secretary of State Susan Lee. “This new facility signals a next chapter of shared success and economic growth that will benefit both Marylanders and the people of Korea for years to come. We are proud to see our enduring alliance translate into tangible, world-class innovation that will improve healthcare outcomes across the globe.”
Recent economic victories under the Moore-Miller Administration include AstraZeneca’s $2 billion investment to expand manufacturing in Frederick and build a new clinical facility in Gaithersburg, supporting 2,600 jobs. The administration has also secured investments from Nature Cell to open a stem cell manufacturing facility in Baltimore City, creating an estimated 500 new jobs, and welcomed Syngene International and SJ Incorporation, whose expansions are expected to add 600 skilled positions to the state’s workforce.
With one of the nation’s largest clusters of life sciences companies, Maryland has a community of nearly 5,000 life science businesses that support a workforce of more than 54,000 employees and $7.3 billion in total wages. By choosing Maryland, life science companies gain unparalleled proximity to leading in-state federal institutions such as the National Institutes of Health, the National Institute of Standards and Technology, and the Food and Drug Administration; in addition to top research institutions such as Johns Hopkins University and the University of Maryland.
